Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation Research & Development Review Pathway

Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed

  • News

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

You may also be interested in...



Keeping Track: Some Calm Before The Storm

The latest drug development news and highlights from our US FDA Performance Tracker.

A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers

Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.

Keeping Track: A Second Straight Burst Of FDA Approvals

The latest drug approval and development news from our US FDA Performance Tracker.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip
Pink Sheet

Topics

Related Companies

Tags:
Regulation Research & Development Review Pathway
Latest Headlines

Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma

Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

Medicare Rx Negotiation Horizon: The Key Dates Ahead Of 2026 Rollout Of The Pricing Program

EU Health Chief Under Pressure To Explain Delay In Legislative Overhaul

See All
UsernamePublicRestriction

Register

PS121106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By